Evidence map›Paper›PMID 36287942›Full record

ArticleToxins2022

Cytokine and Chemokine Retention Profile in COVID-19 Patients with Chronic Kidney Disease.

Paola Ciceri, Valeria Bono, Lorenza Magagnoli, Matteo Sala, Antonella d'Arminio Monforte, Andrea Galassi, Alessandra Barassi, Giulia Marchetti, Mario Cozzolino

Open access · goldAbstract read
In one paragraph

Article in Toxins, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Paola CiceriDepartment of Health Sciences, Renal Division, ASST Santi Paolo e Carlo, University of Milan, 20142 Milan, Italy.
Valeria BonoDepartment of Health Sciences, Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, University of Milan, 20142 Milan, Italy.
Lorenza MagagnoliDepartment of Health Sciences, Renal Division, ASST Santi Paolo e Carlo, University of Milan, 20142 Milan, Italy.ORCID 0000-0003-2853-1332
Matteo SalaDepartment of Health Sciences, Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, University of Milan, 20142 Milan, Italy.
Antonella d'Arminio MonforteDepartment of Health Sciences, Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, University of Milan, 20142 Milan, Italy.ORCID 0000-0003-0073-1789
Andrea GalassiDepartment of Health Sciences, Renal Division, ASST Santi Paolo e Carlo, University of Milan, 20142 Milan, Italy.
Alessandra BarassiLaboratory of Clinical Biochemistry, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, 20142 Milan, Italy.
Giulia MarchettiDepartment of Health Sciences, Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, University of Milan, 20142 Milan, Italy.
Mario CozzolinoDepartment of Health Sciences, Renal Division, ASST Santi Paolo e Carlo, University of Milan, 20142 Milan, Italy.ORCID 0000-0002-8494-6252
University of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic kidney disease (CKD) patients are more susceptible to infections compared to the general population. SARS-CoV-2 virus pathology is characterized by a cytokine storm responsible for the systemic inflammation typical of the COVID-19 disease. Since CKD patients have a reduced renal clearance, we decided to investigate whether they accumulate harmful mediators during the COVID-19 disease. We conducted a retrospective study on 77 COVID-19 hospitalized subjects in the acute phase of the illness. Thirteen different cytokines were assessed in plasma collected upon hospitalization. The patients were divided into three groups according to their estimated glomerular filtration rate, eGFR < 30 (n = 23), 30 < eGFR < 60 (n = 33), eGFR > 60 mL/min (n = 21). We found that Tumor Necrosis Factor α and its receptors I and II, Interleukin-7, Leukemia Inhibitory Factor, FAS receptor, Chitinase 3-like I, and the Vascular Endothelial Growth Factor showed an increased accumulation that negatively correlate with eGFR. Moreover, non-survivor patients with an impaired kidney function have significantly more elevated levels of the same mediators. In conclusion, there is a tendency in COVID-19 ESRD patients to accumulate harmful cytokines. The accumulation seems to associate with mortality outcomes and may be due to reduced clearance but also to increased biosynthesis in most severe cases.

Indexed as

ChitinasesCOVID-19Renal InsufficiencyRenal Insufficiency, ChronicChemokinesCytokinesfas ReceptorGlomerular Filtration RateHumansInterleukin-7Leukemia Inhibitory FactorRetrospective StudiesSARS-CoV-2Tumor Necrosis Factor-alphaVascular Endothelial Growth Factor AChemokinesChitinasesCytokinesfas ReceptorInterleukin-7Leukemia Inhibitory FactorTumor Necrosis Factor-alphaVascular Endothelial Growth Factor ACKDCOVID-19eGFRmortality

Identifiers

PMID36287942
PMCPMC9611576
OpenAlexW4298003643

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.